HKSE · 2877.HK
China Shineway Pharmaceutical Group Limited
HK$7.51+HK$0.23 (+3.09%)
China Shineway Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 28.32% below the high.
Loading market information…
OTC · PMXSF · USD
Stock price, earnings
Quote as of Feb 4, 2026, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pharmaxis Ltd’s next earnings report is currently expected on Feb 5, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pharmaxis Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pharmaxis Ltd, an Australian biopharmaceutical company established in 1998 and headquartered in Frenchs Forest, specializes in the global research, development, and commercialization of therapeutic products for fibrotic and inflammatory diseases. Its business is organized into two main divisions: the Mannitol Respiratory Business and New Drug Development. The company currently markets Bronchitol, an inhaled dry powder medication for the treatment of cystic fibrosis, and Aridol, a diagnostic tool used to detect hyper-responsive airways and assist in the diagnosis and management of asthma. Pharmaxis also has a robust development pipeline featuring several investigational therapies. These include oral pan-lysyl oxidase (LOX) inhibitors aimed at myelofibrosis and various cancers; topical pan-LOX inhibitors designed to minimize skin scarring after events such as accidents, surgery, or burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic conditions like kidney, pulmonary, liver, and cardiac fibrosis; and compounds focused on neuroinflammatory diseases via semicarbazide-sensitive amine oxidase. Furthermore, the company is developing Orbital, a dry powder inhaler intended for the efficient delivery of high drug doses to the lungs.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$7.51+HK$0.23 (+3.09%)
China Shineway Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 28.32% below the high.
$0.17$0.00 (0.0%)
IntelGenx Technologies Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
£0.04-£0.00 (-8.96%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 70.04% below the high.
$0.03+$0.00 (+2.04%)
Hempstract, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.04% below the high.
$0.22$0.00 (0.0%)
Generation Hemp, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.7% below the high.
$0.05+$0.02 (+48.84%)
Chill Brands Group PLC’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
€3.04-€0.01 (-0.33%)
Biofrontera AG’s quoted price sits in the lower half of its reported 52-week range, 41.31% below the high.
$0.16-$0.03 (-15.36%)
TPCO Holding Corp.’s quoted price sits in the lower half of its reported 52-week range, 83.81% below the high.
